Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022)
Theravance Biopharma (TBPH) reported Debt to Equity of -$1.13 for Q2 2022, up 10.96% year-over-year from -$1.02 in Q2 2021, and down 1.22% quarter-over-quarter from -$1.12 in Q1 2022.
Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has 5 years of Debt to Equity data on file, last reported at -$1.13 in Q2 2022.
- Debt to Equity for Q2 2022 came in at -$1.13, up 10.96% year-over-year; the trailing twelve-month figure through Jun 2022 was -$1.13 (up 10.96% YoY), and the FY2021 annual result was -$1.15, up 11.18% from the prior year.
- Debt to Equity fell to -$1.13 in Q2 2022 per TBPH's latest filing, from -$1.12 in the prior quarter.
- Over five years, Debt to Equity peaked at -$1.02 in Q4 2019 and troughed at -$4.45 in Q4 2018.
- A 5-year average of -$1.62 and a median of -$1.27 in 2021 frame the typical range for Debt to Equity.
- The sharpest annual moves came in 2019 and 2020: Debt to Equity jumped 76.99% in 2019, then retreated 26.13% in 2020.
- A 5-year view of Debt to Equity shows it stood at -$4.45 in 2018, then jumped by 76.99% to -$1.02 in 2019, then decreased by 26.13% to -$1.29 in 2020, then rose by 11.18% to -$1.15 in 2021, then grew by 1.26% to -$1.13 in 2022.
- Business Quant data shows TBPH's Debt to Equity at -$1.13 in Q2 2022, -$1.12 in Q1 2022, and -$1.15 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -1.13 |
| Mar 31, 2022 | -1.12 |
| Dec 31, 2021 | -1.15 |
| Sep 30, 2021 | -1.20 |
| Jun 30, 2021 | -1.27 |
| Mar 31, 2021 | -1.04 |
| Dec 31, 2020 | -1.29 |
| Sep 30, 2020 | -1.47 |
| Jun 30, 2020 | -1.85 |
| Mar 31, 2020 | -2.37 |
| Dec 31, 2019 | -1.02 |
| Sep 30, 2019 | -1.26 |
| Jun 30, 2019 | -1.68 |
| Mar 31, 2019 | -2.03 |
| Dec 31, 2018 | -4.45 |